![Molecules | Free Full-Text | Precise Quantification of Molybdate In Vitro by the FRET-Based Nanosensor ‘MolyProbe’ Molecules | Free Full-Text | Precise Quantification of Molybdate In Vitro by the FRET-Based Nanosensor ‘MolyProbe’](https://pub.mdpi-res.com/molecules/molecules-27-03691/article_deploy/html/images/molecules-27-03691-ag-550.jpg?1654685389)
Molecules | Free Full-Text | Precise Quantification of Molybdate In Vitro by the FRET-Based Nanosensor ‘MolyProbe’
Development of 2-in-1 Sensors for the Safety Assessment of Lithium-Ion Batteries via Early Detection of Vapors Produced by Electrolyte Solvents | ACS Applied Materials & Interfaces
![Development of 2-in-1 Sensors for the Safety Assessment of Lithium-Ion Batteries via Early Detection of Vapors Produced by Electrolyte Solvents | ACS Applied Materials & Interfaces Development of 2-in-1 Sensors for the Safety Assessment of Lithium-Ion Batteries via Early Detection of Vapors Produced by Electrolyte Solvents | ACS Applied Materials & Interfaces](https://pubs.acs.org/cms/10.1021/acsami.3c03564/asset/images/large/am3c03564_0002.jpeg)
Development of 2-in-1 Sensors for the Safety Assessment of Lithium-Ion Batteries via Early Detection of Vapors Produced by Electrolyte Solvents | ACS Applied Materials & Interfaces
![The biological seal of the implant–soft tissue interface evaluated in a tissue-engineered oral mucosal model | Journal of The Royal Society Interface The biological seal of the implant–soft tissue interface evaluated in a tissue-engineered oral mucosal model | Journal of The Royal Society Interface](https://royalsocietypublishing.org/cms/asset/053f056f-c2b9-4a05-8aa7-8740452f5701/rsif20120507f10.jpg)
The biological seal of the implant–soft tissue interface evaluated in a tissue-engineered oral mucosal model | Journal of The Royal Society Interface
![Revolutionizing Atopic Dermatitis, 9–11 April 2022 - 2022 - British Journal of Dermatology - Wiley Online Library Revolutionizing Atopic Dermatitis, 9–11 April 2022 - 2022 - British Journal of Dermatology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/178d2d2d-628b-4ca6-8faf-df00490ea829/bjd21666-fig-0005-m.jpg)
Revolutionizing Atopic Dermatitis, 9–11 April 2022 - 2022 - British Journal of Dermatology - Wiley Online Library
![Process intensification in biopharmaceutical process development and production – an industrial perspective Process intensification in biopharmaceutical process development and production – an industrial perspective](https://www.degruyter.com/document/doi/10.1515/psr-2022-0113/asset/graphic/j_psr-2022-0113_fig_007.jpg)
Process intensification in biopharmaceutical process development and production – an industrial perspective
![The role of tralokinumab in the treatment of atopic dermatitis and future perspectives for adolescents | Immunotherapy The role of tralokinumab in the treatment of atopic dermatitis and future perspectives for adolescents | Immunotherapy](https://www.futuremedicine.com/cms/10.2217/imt.2023.15.issue-16/asset/17b343c7-3617-343c-7361-b343c773617b/cover.jpg)
The role of tralokinumab in the treatment of atopic dermatitis and future perspectives for adolescents | Immunotherapy
![IJERPH | Free Full-Text | Referral Patterns in Oral Medicine: A Retrospective Analysis of an Oral Medicine University Center in Southern Italy IJERPH | Free Full-Text | Referral Patterns in Oral Medicine: A Retrospective Analysis of an Oral Medicine University Center in Southern Italy](https://www.mdpi.com/ijerph/ijerph-18-12161/article_deploy/html/images/ijerph-18-12161-g001.png)
IJERPH | Free Full-Text | Referral Patterns in Oral Medicine: A Retrospective Analysis of an Oral Medicine University Center in Southern Italy
![Frontiers | RNA Sequencing Keloid Transcriptome Associates Keloids With Th2, Th1, Th17/Th22, and JAK3-Skewing Frontiers | RNA Sequencing Keloid Transcriptome Associates Keloids With Th2, Th1, Th17/Th22, and JAK3-Skewing](https://www.frontiersin.org/files/Articles/597741/fimmu-11-597741-HTML-r1/image_m/fimmu-11-597741-g001.jpg)
Frontiers | RNA Sequencing Keloid Transcriptome Associates Keloids With Th2, Th1, Th17/Th22, and JAK3-Skewing
![Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO) - Pinter - 2022 - Journal of the European Academy of Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO) - Pinter - 2022 - Journal of the European Academy of](https://onlinelibrary.wiley.com/cms/asset/2acb1074-8e7c-499f-a853-f287a41fd642/jdv.v36.11.cover.jpg?trick=1699155776263)
Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO) - Pinter - 2022 - Journal of the European Academy of
![Bundesheer - Sport im Bundesheer - Fotogalerien - Bereichsmeisterschaften Ost, 2006; Patrouillenlauf Bundesheer - Sport im Bundesheer - Fotogalerien - Bereichsmeisterschaften Ost, 2006; Patrouillenlauf](https://www.bmlv.gv.at/sport/galerie/vollbild/bmschi06_pat_mac_tuepls_i.jpg)
Bundesheer - Sport im Bundesheer - Fotogalerien - Bereichsmeisterschaften Ost, 2006; Patrouillenlauf
![Re-irradiation in clinical practice: Results of an international patterns of care survey within the framework of the ESTRO-EORTC E2-RADIatE platform - ScienceDirect Re-irradiation in clinical practice: Results of an international patterns of care survey within the framework of the ESTRO-EORTC E2-RADIatE platform - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0167814023898413-ga1.jpg)
Re-irradiation in clinical practice: Results of an international patterns of care survey within the framework of the ESTRO-EORTC E2-RADIatE platform - ScienceDirect
![PDF) Secukinumab Demonstrates High Sustained Efficacy and a Favorable Safety Profile in Patients with Moderate to Severe Psoriasis through 5 Years of Treatment (SCULPTURE Extension Study) PDF) Secukinumab Demonstrates High Sustained Efficacy and a Favorable Safety Profile in Patients with Moderate to Severe Psoriasis through 5 Years of Treatment (SCULPTURE Extension Study)](https://i1.rgstatic.net/publication/323194013_Secukinumab_Demonstrates_High_Sustained_Efficacy_and_a_Favorable_Safety_Profile_in_Patients_with_Moderate_to_Severe_Psoriasis_through_5_Years_of_Treatment_SCULPTURE_Extension_Study/links/5afdc869458515e9a53280d5/largepreview.png)